
Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.9K
- Following3K
- Followers8.5K
- Likes19.4K
🔥off the press : #ALNEO: Phase 2 trial of #Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III AlK+ NSCLC
▶️N=33 pts
▶️ Alectinib for 8 weeks preop
followed by 2 yrs adjuvant
🎯MPR 42% (primary endpoint met), pCR 12%
🎯ORR 67%; 85% underwent surgery, R0 in 86%
👉🏽Trial too small to answer what is the survival advantage of perioperative vs adjuvant ALK+ therapy
👉🏽could there be patients that could benefit from chemo?
🎙 @Ale_leonetti at al
#LCSM @ALKPositiveinc
via @JCO_ASCO | ascopubs.org/doi/10.1200/JCO…
Dr. Estela Rodriguez retweeted
Insightful lecture by Dr. Devarakonda on ADCs in SCLC.
Encouraging activity across several ADCs, including recent B7-H3 ADC data at WCLC 2026.
Exciting potential, with ongoing evaluation in 1L/2L. Key questions remain around biomarkers, toxicity, sequencing.
#MaTOS26
Dr. Estela Rodriguez retweeted
You might think of a couch when you think of #therapy.
This is the #localtherapy couch. IYKYK
🫁☢️🔪😷
#MaTOSLung 2026 #LungCancer @tssmn
Dr. Estela Rodriguez retweeted
From idea to a published study, every research project has a starting point. Dr. @Jani_Chinmay is moderating "From Idea to Publication: Building Research," with Drs. @DrKazandjian, @GlopesMd, @VamsiVelcheti, and @DVAraujoMD. An exciting conversation for our future investigators!
Don’t miss this session with @FLASCO_ORG @HemOncFellows fellowship program directors to learn about how to improve your application. 👇
What do fellowship program directors want future fellows to know? Drs. Noman Ashraf, @RManochakian, Janaki Sharma and Carol Mathew join moderator @DocOncMD for "The Fellowship Playbook," sharing perspectives on preparing for fellowship and making the most of training. #FLASCO
Dr. Estela Rodriguez retweeted
Important work highlighted at #MaTOSLung from Gerard Silvestri @JAMAOnc - in 250,000 older patients with metastatic lung cancer diagnosed 2006-21, only 46.8% received any systemic therapy. More likely to be treated: referral to an oncologist, low co-morbidity burden, being married, survival of 90d.
We have much more effective and well tolerated treatments for lung cancer - we need to improve access, overcome stigma, and make sure everyone has a chance to benefit from all of the progress we have made over the past few years.
jamanetwork.com/journals/jam…
#MaTOS26 @NaglaAKarimMD @GWtweets brings the “Habibi” energy with a spirited and colorful argument against @WadeIams for lurbinectedin over tarlatamab + durvalumab (DeLLphi-305) as maintenance therapy in ES-SCLC. A great debate on the evolving treatment landscape! #LCSM @SclcSMASHERS
#MaTOS26 Best part of this meeting: multidisciplinary roundtables with experts from across the country, sharing experiences and perspectives where data are limited—from targeted therapies in the perioperative setting to defining borderline-resectable disease.
🙏Grateful to be part of these conversations that move the field forward! #LCSM @SylvesterCancer
Dr. Estela Rodriguez retweeted
1/ GameDay is in Coral Gables today, so let's settle something. The Hurricanes' last national championship was January 3, 2002 — 37–14 over Nebraska in the Rose Bowl. If you watched that game live as an adult, you're about 50 now.
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwivtch
Should 40 year old never smokers get lung cancer screening ?
-on the potential risks and benefits of earlier screening on the general population.
story via @CNN : cnn.com/2026/11/20/health/vi…
Dr. Estela Rodriguez retweeted
At MaTOS Lung 2026, every conversation has a purpose.
Leading experts in lung cancer are coming together to share emerging clinical evidence, discuss evolving treatment strategies, and explore new approaches that can help shape better care for patients.
The value of this meeting goes beyond the sessions. It is about exchanging perspectives, challenging current thinking, and bringing meaningful clinical insights back into practice.
Because progress in lung cancer care depends on continued learning, collaboration, and a shared commitment to improving outcomes.
United in Every Breath.
#MaTOS #MaTOSLung #UnitedInEveryBreath #LungCancer #ThoracicOncology #OncologyEducation #MedicalEducation #ClinicalInsights #CancerCare #PatientCare
@DasMillie11
@delvysra
@DDoroshow
@lungoncdoc
@BalazsHalmosMD
@WadeIams
@ReckampK
@yyelamin
@JustinGainor
@NaglaAKarimMD
@LauraAlderMD
@LindaMThoracic
@BenCreelan
@triparnasen
@DCarboneMD
@luisraezmd
@md_hsu
@Joshua_Reuss
@lexiuning
@Latinamd
@drshieldsmd @SCLCSMASHERS
@CoreyLanger
@EddieSantosMD
@collin_blakely
@ShirishGadgeel
@christine_lovly
@chulkimMD
@MattGubensMD
@hosseinborghaei
@StephenVLiu
@iyengarpuneeth
@ChaftJamie
@maryjofidlermd
@BRicciutiMD
@MNagasaka
#MaTOS26 Dr. Tina Cascone @UTMDAnderson, the reigning queen 👑 of perioperative chemo-IO, takes the stage and makes a compelling case in the debate on ctDNA in early-stage lung cancer (against @HosseinBorghaei) for surveillance , clinical trial integration, and guiding treatment escalation or de-escalation. 🔥 #LCSM
So happy to see Dr. @MPatriciaRivera again at #MaTOS26 ! ❤️ She is one of the @LatinasInMed leaders I truly admire and feel fortunate to know. Her leadership, passion, and dedication to advancing lung cancer screening and addressing barriers to care continue to inspire me. Grateful for her friendship and for the example she sets for all of us. #WomenInMedicine #LCSM #WomeninThoracicMedicine #WomenLead #SheforShe
1
19
503
#MaTOS26 Dr. Jay Lee @UCLAHealth reviews perioperative chemo-IO and survival outcomes in resectable NSCLC.
The shift to induction therapy has happened. What’s missing?
▶️Identifying who benefits most, ▶️isolating the adjuvant contribution, and
▶️personalizing surgery vs. chemoradiation in borderline cases #LCSM
Should lung cancer surveillance stop at 5 years? New data from a Korean population based cohort ( 55K patients) suggest otherwise. Continued CT surveillance beyond 5 years was associated with a 34% lower all-cause mortality rate (2.62% vs. 4.33% annually),
👉🏽highlighting the importance of detecting late recurrences and second primary lung cancers. #LCSM
Chest CT Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival via @JAMAOnc
jamanetwork.com/journals/jam…
2
209
Dr. Estela Rodriguez retweeted
Should all pts get NGS even for early stage NSCLC?
@LudaBazhenovaMD leads a panel on perioperative NGS #MaTOSLung2026
w/ @JDoningtonmd @Fred_Hirsch @WadeIams @KHigginsMD @LatinaMD @RachelSanbornMD
Dr. Estela Rodriguez retweeted
No one facing cancer should have to worry about where their next meal will come from. You can help keep nutritious food on the table for Sylvester patients and their families.
In just over a year, our food pantry has supported more than 500 patients and distributed more than 1,400 bags of groceries to patients and families. This year, the number of patients we serve each week has doubled.
Your gift will help us reach our goal as we work to expand food assistance to our Kendall and Plantation locations, bringing groceries closer to where more patients receive care. Donate today: spr.ly/6018BywOti. #GiveMiamiDay
#MaTOS26 @MPatriciaRivera @UofR makes
the case that the future of lung cancer screening
lies in a more personalized approach integrating clinical risk assessment and blood-based biomarkers to improve early detection. #lcsm #ctDNA #lungcancerscreening
#MaTOS26 Day 1 Dr @jdoningtonmd @UofC starts the meeting w a great discussion on the challenges of lung cancer screening!
20 years after the first I-ELCAP 🫁 screening publication, we screen only ~24% of eligible individuals, and annual adherence remains below 50%.
How do we close the gap?
Better educate primary care,
raise public awareness, and simplify the screening process!
#LungCancerScreening #LCSM































